Pear Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PEAR research report →
About the company
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia.
- CEO
- Christopher D. T. Guiffre MBA
- IPO
- 2021
- Employees
- 200
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $4.09M
- P/E
- -0.17
- P/S
- 0.32
- P/B
- 0.13
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 35.54%
- Op Margin
- -971.72%
- Net Margin
- -187.02%
- ROE
- -39.23%
- ROIC
- -51.64%
- Revenue
- $12.69M · 201.66%
- Net Income
- $-23,740,000 · -16.98%
- EPS
- $-0.17 · 5.56%
- Op Income
- $-123,350,000
- FCF YoY
- -3.25%
- 52W High
- $6.74
- 52W Low
- $0.01
- 50D MA
- $0.43
- 200D MA
- $1.43
- Beta
- 0.52
- Avg Volume
- 10.09M
Get TickerSpark's AI analysis on PEAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 23 | 5AM Partners IV, LLC | sell | 3,172,769 |
| Apr 10, 23 | 5AM Partners IV, LLC | sell | 534,855 |
| Feb 15, 23 | Snow Ellen | other | 199,864 |
| Feb 16, 23 | Snow Ellen | other | 40,000 |
| Feb 15, 23 | Brenner Erin K. | other | 952,380 |
| Feb 15, 23 | O'Brien Ronan | other | 1,295,238 |
| Feb 15, 23 | Maricich Yuri | other | 1,333,333 |
| Feb 15, 23 | Strandberg Julia | other | 1,409,523 |
| Feb 15, 23 | GUIFFRE CHRISTOPHERD T | other | 2,285,714 |
| Feb 15, 23 | McCann Corey | other | 2,857,142 |
Our PEAR coverage
Recent articles, reports, and earnings notes.
No research on PEAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PEAR report →Similar companies
Peers in the same neighborhood.